| Literature DB >> 24624088 |
Gabriele G Schiattarella1, Cinzia Perrino1, Fabio Magliulo1, Andreina Carbone1, Antonio G Bruno1, Michele De Paulis1, Antonio Sorropago1, Roberto V Corrado1, Roberta Bottino1, Giovanni Menafra1, Raffaele Abete1, Evelina Toscano1, Giuseppe Giugliano1, Bruno Trimarco1, Giovanni Esposito1.
Abstract
Aging is a well-known cardiovascular risk factor and cardiovascular diseases (CVD) are estimated to be the most common cause of death in the elderly. Peripheral arterial disease (PAD) represents an important clinical manifestation of CVD leading to increase morbidity and mortality, especially in elderly population. The correct management of PAD population includes the prevention of cardiovascular events and relief of symptoms, most commonly intermittent claudication. Progressive physical activity is an effective treatment to improve walking distance and to reduce mortality and cardiovascular events in patients with PAD, however the ability to effectively engage in physical activity often declines with increasing age. The maintenance and increase of reserve functional capacity are important concepts in the elderly population. Ultimately, the goal in participation of physical activity in the healthy elderly population is maintenance and development of physical functional reserve capacity. Therefore, for individuals suffering of PAD, appropriate physical activity in the form of supervised exercise may serve as a primary therapy. Although there are few direct comparisons of therapeutic exercise programs vs. pharmacological or surgical interventions, these increases in walking distance are greater than those reported for the most widely used agents for claudication, pentoxyphylline, and cilostazol. Despite a reduction in mortality and improvement of quality of life caused by physical activity in the PAD population, the molecular, cellular, and functional changes that occur during physical activity are not completely understood. Therefore, this review article aims at presenting an overview of recent established clinical and molecular findings addressing the role of physical activity on PAD in the older population.Entities:
Keywords: PAD; aging; atherosclerosis; claudication; exercise; fitness
Year: 2014 PMID: 24624088 PMCID: PMC3939939 DOI: 10.3389/fphys.2014.00012
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Nutraceutical and prevention of cardiovascular disease.
| Vitamin C | 800 mg daily | Antioxidant properties |
| Preserved endothelial function | ||
| Poor evidences in human studies (no reduction in major CV events) | ||
| Vitamin E | 600 mg daily | Antioxidant properties |
| Significant reduction in urinary tromboxane concentration | ||
| No evidences for routine use | ||
| Calcium citrate + vitamin D3 | 500 mg + 700 IU daily | In healthy adults supplementation may attenuate glycemia increase |
| Prevention of ostheoporosis | ||
| Flavonoids (such as quercetin, myricetin, naringemin, hesperetin) | Various dosages | Risk reduction of diabetes mellitus |
| Decreased incidence of ischemic heart disease and mortality after AMI | ||
| Lower incidence of CV death and morbidity | ||
| Omega-3-Fatty acid | 1000 mg tid | Decrease blood triglycerides levels |
| Prevent atherosclerosis | ||
| Inconsistent data in secondary prevention of CV diseases | ||
| Chromium | 300 μg daily of elemental Cr (III) | Mean fasting glucose levels lowered |
| Zinc sulfate 200 mg daily | 200 mg daily | Modest benefit of treatment |
| α-lipoic acid | 600 mg/day | Increase in insulin-resistance |
| Resveratol | 50 mg/day | Block endothelial senescence |
| Lower serum lipids and arterial pressure | ||
| Decrease inflammation |
CV, cardiovascular; IU, international units; AMI, acute myocardial infarction; tid, three time a day.